Bausch + Lomb is also seeking regulatory approvals in other markets for the enVista Envy IOL. Credit: megaflopp / Shutterstock.com.

Eye health company Bausch + Lomb has secured regulatory approval from Health Canada for its enVista Envy full visual range intraocular lens (IOL).

Built on the enVista IOL platform, the new lens is designed to provide patients with a full range of vision and high tolerance to dysphotopsia, a common issue with glare and halos post-surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A multicentre, randomised, and controlled clinical trial in Canada has shown promising long-term outcomes with the enVista Envy IOL.

Notably, 93% of patients experienced minimal dysphotopsia, and 94% had little to no difficulty with near vision while maintaining excellent distance vision without glasses, offering a continuous visual range of four dioptres.

The enVista Envy IOL incorporates ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision across various lighting conditions and reducing light scattering.

Additionally, the enVista Envy IOL’s Low-Cyl toric technology addresses both presbyopia and low levels of astigmatism, providing more precise correction with 0.5D steps or less throughout the cylinder range.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bausch + Lomb global surgical president Luc Bonnefoy said: “enVista Envy is the next step in the dramatic transformation of our IOL portfolio.

“This first premium IOL on the enVista platform follows the US launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”

The enVista Envy IOLs aim to be commercially available in Canada next month.

Bausch + Lomb is also seeking regulatory approvals in other markets, including the US and Europe, for the enVista Envy IOL.

Last year, Bausch and Lomb and Heidelberg Engineering launched the new SeeLumafully digital surgical visualisation platform.